Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 6Neoplasm Metastasis 2Liver Neoplasms 2Colorectal Neoplasms 2Pancreatic Neoplasms 1Conversion Disorder 1Colonic Neoplasms 1Abdominal Injuries 1

Interventions

Bevacizumab 119Fluorouracil 91Leucovorin 83Cetuximab 83Oxaliplatin 80pembrolizumab 70Irinotecan 67Nivolumab 46Capecitabine 43Specimen Handling 40regorafenib 30Folfox protocol 29trifluridine tipiracil drug combination 28Magnetic Resonance Spectroscopy 27Biopsy 27Panitumumab 26Standard of Care 25HMPL-013 25IFL protocol 21Gemcitabine 20Blood Specimen Collection 19atezolizumab 18Trifluridine 18Cisplatin 18tislelizumab 17balstilimab 16Colonoscopy 16Carboplatin 16encorafenib 15Paclitaxel 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Hepatectomy × 1 year × Clear all
NCT07612007 2026-06-01

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Mayo Clinic

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT03844750 2025-12-31

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

University of California, San Francisco

Phase 2 Terminated
6 enrolled 12 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡